+ Watch IMMU
on My Watchlist
A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
A big winner or hype?The idea of creating antibodies to difficult to treat tumor cells and then attaching the antibody to a toxic agent to selectively kill tumor cells has been around for a while. Did this company find a way to do this cost effectively and with adequate safety?If is works, will there be funding for it?With this price spike, some people must believe in it, but even good idea can die in this market.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions